Skip to main content
PMC home page
Gut logoLink to Gut
. 1988 May;29(5):669–674. doi: 10.1136/gut.29.5.669

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.

S A Riley 1, V Mani 1, M J Goodman 1, M E Herd 1, S Dutt 1, L A Turnberg 1
PMCID: PMC1433642  PMID: 2899536

Abstract

Oral formulations of 5-aminosalicylic acid (mesalazine) appear less toxic than sulphasalazine. We have therefore compared sulphasalazine, low dose mesalazine and high dose mesalazine in the treatment of mild to moderate relapse of ulcerative colitis. Sixty one patients (32 men, aged 20-78 years) were randomly allocated to sulphasalazine 2 g daily, mesalazine 800 mg daily, or mesalazine 2.4 g daily in a double blind, double dummy, four week trial. Groups were comparable for age, sex, extent of disease, and pretrial sulphasalazine intake. Four patients were unable to complete the study because of treatment failure (two taking sulphasalazine and two high dose mesalazine). A further two patients taking sulphasalazine developed side effects necessitating withdrawal. Within treatment comparisons revealed significant improvement of: sigmoidoscopic grade in the sulphasalazine group; rectal bleeding, sigmoidoscopic and histological grade in the low dose mesalazine group; stool frequency, rectal bleeding and sigmoidoscopic grade in the high dose mesalazine group. Greater improvement in rectal bleeding (p less than 0.05) and sigmoidoscopic appearances (p less than 0.05) occurred in patients taking high dose mesalazine than in those taking sulphasalazine. In two patients taking high dose mesalazine minor rises of plasma creatinine concentrations occurred, suggesting the need to monitor renal function.

Full text

PDF
669

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azad Khan A. K., Howes D. T., Piris J., Truelove S. C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  3. BARON J. H., CONNELL A. M., LENNARD-JONES J. E., JONES F. A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962 May 26;1(7239):1094–1096. doi: 10.1016/s0140-6736(62)92080-9. [DOI] [PubMed] [Google Scholar]
  4. Bown R. L., Gibson J. A., Sladen G. E., Hicks B., Dawson A. M. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut. 1974 Dec;15(12):999–1004. doi: 10.1136/gut.15.12.999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Briggs D., Calder I., Woods R., Tange J. The influence of metabolic variation on analgesic nephrotoxicity. Experiments with the Gunn rat. Pathology. 1982 Oct;14(4):349–353. doi: 10.3109/00313028209092108. [DOI] [PubMed] [Google Scholar]
  6. Calder I. C., Funder C. C., Green C. R., Ham K. N., Tange J. D. Comparative nephrotoxicity of aspirin and phenacetin derivatives. Br Med J. 1971 Nov 27;4(5786):518–521. doi: 10.1136/bmj.4.5786.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Calder I. C., Funder C. C., Green C. R., Ham K. N., Tange J. D. Nephrotoxic lesions from 5-aminosalicylic Acid. Br Med J. 1972 Jan 15;1(5793):152–154. doi: 10.1136/bmj.1.5793.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Campieri M., Lanfranchi G. A., Bazzocchi G., Brignola C., Sarti F., Franzin G., Battocchia A., Labo G., Dal Monte P. R. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981 Aug 8;2(8241):270–271. doi: 10.1016/s0140-6736(81)90523-7. [DOI] [PubMed] [Google Scholar]
  9. Campieri M., Lanfranchi G. A., Boschi S., Brignola C., Bazzocchi G., Gionchetti P., Minguzzi M. R., Belluzzi A., Labò G. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut. 1985 Apr;26(4):400–405. doi: 10.1136/gut.26.4.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Campieri M., Lanfranchi G. A., Brignola C., Bazzocchi G., Minguzzi M. R., Calari M. T. 5-aminosalicylic acid as rectal enema in ulcerative colitis patients unable to take sulphasalazine. Lancet. 1984 Feb 18;1(8373):403–403. doi: 10.1016/s0140-6736(84)90462-8. [DOI] [PubMed] [Google Scholar]
  11. DICK A. P., GRAYSON M. J., CARPENTER R. G., PETRIE A. CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS. Gut. 1964 Oct;5:437–442. doi: 10.1136/gut.5.5.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Das K. M., Eastwood M. A., McManus J. P., Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973 Sep 6;289(10):491–495. doi: 10.1056/NEJM197309062891001. [DOI] [PubMed] [Google Scholar]
  13. Dew M. J., Harries A. D., Evans B. K., Rhodes J. Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine. Lancet. 1983 Oct 1;2(8353):801–801. doi: 10.1016/s0140-6736(83)92341-3. [DOI] [PubMed] [Google Scholar]
  14. Dew M. J., Harries A. D., Evans N., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br Med J (Clin Res Ed) 1983 Jul 2;287(6384):23–24. doi: 10.1136/bmj.287.6384.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dew M. J., Hughes P. J., Lee M. G., Evans B. K., Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol. 1982 Sep;14(3):405–408. doi: 10.1111/j.1365-2125.1982.tb01999.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dew M. J., Hughes P., Harries A. D., Williams G., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1982 Oct 9;285(6347):1012–1012. doi: 10.1136/bmj.285.6347.1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Diener U., Tuczek H. V., Fischer C., Maier K., Klotz U. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol. 1984 Jun;326(3):278–282. doi: 10.1007/BF00505331. [DOI] [PubMed] [Google Scholar]
  18. Dissanayake A. S., Truelove S. C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut. 1973 Dec;14(12):923–926. doi: 10.1136/gut.14.12.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Donald I. P., Wilkinson S. P. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine. Postgrad Med J. 1985 Dec;61(722):1047–1048. doi: 10.1136/pgmj.61.722.1047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Haagen Nielsen O., Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol. 1983 Dec;16(6):738–740. doi: 10.1111/j.1365-2125.1983.tb02254.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
  22. LENNARD-JONES J. E., LONGMORE A. J., NEWELL A. C., WILSON C. W., JONES F. A. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut. 1960 Sep;1:217–222. doi: 10.1136/gut.1.3.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Riley S. A., Lecarpentier J., Mani V., Goodman M. J., Mandal B. K., Turnberg L. A. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. Gut. 1987 Aug;28(8):1008–1012. doi: 10.1136/gut.28.8.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sutherland L. R., Martin F., Greer S., Robinson M., Greenberger N., Saibil F., Martin T., Sparr J., Prokipchuk E., Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987 Jun;92(6):1894–1898. doi: 10.1016/0016-5085(87)90621-4. [DOI] [PubMed] [Google Scholar]
  25. TRUELOVE S. C., WATKINSON G., DRAPER G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J. 1962 Dec 29;2(5321):1708–1711. doi: 10.1136/bmj.2.5321.1708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Taffet S. L., Das K. M. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci. 1983 Sep;28(9):833–842. doi: 10.1007/BF01296907. [DOI] [PubMed] [Google Scholar]
  27. WATKINSON G. Medical management of ulcerative colitis. Br Med J. 1961 Jan 21;1(5220):147–151. doi: 10.1136/bmj.1.5220.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. van Hees P. A., Bakker J. H., van Tongeren J. H. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980 Jul;21(7):632–635. doi: 10.1136/gut.21.7.632. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES